CPHI on NYSE
CHINA PHARMA HOLDINGS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with XBiotech Inc., CervoMed Inc. or ProPhase Labs, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-3.2%Gross margin3
-78.2%Operating margin3
-76.9%Net margin3
-8.5%Revenue growth, 20253
-14.0%Return on equity3
$88.9KFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue93¢$4.3M
- Research and development6¢$280.9K
- Interest1¢$27.3K
Out of $4.1M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending40¢$59.3K
- Kept or used elsewhere60¢$88.9K
Out of $148.3K of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $4.1M | $4.5M |
| Cost of revenue | $4.3M | $6.5M |
| Gross loss | -$131.9K | -$2.0M |
| Selling expenses | $375.8K | $528.8K |
| General and administrative expenses | $2.5M | $1.8M |
| Research and development expenses | $280.9K | $283.9K |
| Credit (gains) losses | -$1.0K | $5.7K |
| Total operating expenses | $3.1M | $2.6M |
| Loss from operations | -$3.2M | -$4.6M |
| Research and development subsidy | $151.6K | |
| Interest income | $2.0K | $6.6K |
| Interest expense | -$102.0K | -$154.1K |
| Net other income (expense) | $51.5K | -$147.5K |
| Loss before income taxes | -$3.2M | -$4.7M |
| Net loss | -$3.2M | -$4.7M |
| Other comprehensive income (loss) - foreign currency translation adjustment | $263.0K | -$132.4K |
| Comprehensive loss | -$2.9M | -$4.9M |
| Loss per share, basic (in Dollars per share) | -$0.74 | -$2.71 |
| Loss per share, diluted (in Dollars per share) | -$0.74 | -$2.71 |
| Weighted average shares outstanding (in Shares) | 4.3M shares | 1.7M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-08-31 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $345.1K | $626.9K | |
| Bankers acceptances | $18.6K | ||
| Trade accounts receivable, less allowance for credit losses of $13,023 and $13,587,182, respectively | $241.4K | $232.1K | |
| Other receivables, less allowance for doubtful accounts of $32,153 and $28,447, respectively | $49.3K | $30.3K | |
| Advances to suppliers | $6.8K | $15.0K | |
| Inventories | $1.6M | $2.3M | |
| Prepaid expenses | $82.4K | $81.3K | |
| Total Current Assets | $2.3M | $3.3M | |
| Property, plant and equipment, net | $4.4M | $4.9M | |
| Right-of-use assets | $181.8K | $38.3K | |
| Intangible assets, net | $24.1M | $6.7M | |
| TOTAL ASSETS | $31.0M | $14.9M | |
| Trade accounts payable | $891.1K | $225.1K | |
| Accrued expenses | $350.6K | $247.2K | |
| Other payables | $2.6M | $2.2M | |
| Contract liabilities | $111.6K | $162.2K | |
| Borrowings from related parties | $1.4M | $1.1M | |
| Lease liabilities | $71.6K | $39.3K | |
| Current portion of lines of credit | $2.0M | $1.0M | |
| Total Current Liabilities | $7.4M | $5.0M | |
| Lines of credit, net of current portion | $1.4M | ||
| Lease liabilities net of current portion | $111.5K | ||
| Deferred tax liability | $747.8K | $731.2K | |
| Total Liabilities | $8.3M | $7.1M | |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 15,522,002 shares and 3,261,911 shares issued and outstanding, respectively | $15.5K | $3.3K | |
| Additional paid-in capital | $58.5M | $40.6M | |
| Securities purchase agreement receivable | -$180.0K | -$180.0K | |
| Accumulated deficit | -$47.2M | -$44.0M | |
| Accumulated other comprehensive income | $11.6M | $11.3M | |
| Total Stockholders Equity | $22.7M | $7.7M | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $31.0M | $14.9M | |
| Trade accounts receivable, less allowance for credit losses | $13.0K | $13.6M | |
| Other receivables, less allowance for doubtful accounts | $32.2K | $28.4K | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 5.0M shares | 5.0M shares | |
| Common stock, shares par value (in Dollars per share) | $0.00 | $1.39 | $0.00 |
| Common stock, shares authorized (in Shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in Shares) | 15.5M shares | 1.8M shares | 3.3M shares |
| Common stock, shares outstanding (in Shares) | 15.5M shares | 3.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$3.2M | -$4.7M |
| Depreciation and amortization | $1.5M | $2.6M |
| Depreciation of right of use assets | $75.5K | $58.9K |
| Accounts written off to allowance for credit losses | -$13.7M | |
| Financial expense | $3.5K | $2.2K |
| Credit (gains) loss | -$1.0K | $5.7K |
| Provision to write down inventories to net realizable value | $549.2K | $450.7K |
| Trade accounts and other receivables | $13.2M | -$197.7K |
| Advances to suppliers | $8.3K | -$13.1K |
| Inventories | $589.8K | $1.6M |
| Trade accounts payable | $650.3K | -$733.9K |
| Other payables and accrued expenses | $465.8K | $431.2K |
| Contract liabilities | -$53.4K | $73.7K |
| Prepaid expenses | $793 | $27.6K |
| Net Cash Provided by / (Used in) Operating Activities | $148.3K | -$406.1K |
| Purchases of property, plant and equipment, net | -$59.3K | -$38.4K |
| Advances for intangible assets | -$77.9K | -$253.3K |
| Net Cash Used In Investing Activities | -$137.3K | -$291.7K |
| Payments of line of credit | -$1.2M | -$492.8K |
| Proceeds from lines of credit | $700.0K | $492.8K |
| Proceeds from related party | $261.1K | $27.4K |
| Principal payments on finance lease liabilities | -$78.8K | -$61.1K |
| Net Cash Used In Financing Activities | -$294.0K | -$33.8K |
| Effect of Exchange Rate Changes on Cash | $1.2K | -$65.4K |
| Net Decrease in Cash and Cash Equivalents | -$281.8K | -$797.0K |
| Cash paid for interest | $74.8K | $86.8K |
| Issuances of stock for intangible assets | $17.9M | $3.7M |
| Right of Use Assets obtained in exchange for operating lease obligations | $214.7K | |
| Conversions of Note Payable and interest to common stock | $1.5M | |
| Issuance of common for securities purchase agreement | $180.0K |
Former names
Recent filings
- Aug 14, 202610-Q QUARTERLY REPORT
- Jul 23, 2026424B5 PROSPECTUS SUPPLEMENT
- Jul 22, 20268-K CURRENT REPORT
- May 15, 202610-Q QUARTERLY REPORT
- Apr 1, 2026NT 10-K NOTIFICATION OF LATE FILING
- Apr 1, 202610-K ANNUAL REPORT
- Mar 3, 20268-K CURRENT REPORT
- Feb 10, 20268-K CURRENT REPORT
- Jan 6, 20268-K CURRENT REPORT
- Dec 23, 20258-K
- Dec 10, 20258-K CURRENT REPORT
- Nov 14, 2025DEF 14A DEFINITIVE PROXY STATEMENT
- Nov 12, 202510-Q QUARTERLY REPORT
- Nov 4, 2025PRE 14A PRELIMINARY PROXY STATEMENT
- Aug 14, 202510-Q QUARTERLY REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11